Physicians and administrators at some of the nation’s leading Federally Qualified Health Centers (FQHCs) now have the ability to quickly and easily assess liver health to better address the NAFLD epidemic
It’s startling to learn that over 30% of the U.S. population has some degree of non-alcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver and the most common type of liver disease in the Western world
A growing number of healthcare providers are adopting FibroScan, a non-invasive technology to examine patient’s liver at the point of care.
Hear from two of our global leaders, Dominique Legros and Jon Gingrich, how Echosens is poised for exceptional growth as we focus on the assessment of chronic liver disease against the looming worldwide epidemic of NAFLD.
After reaching the goal of 100,000 veterans cured of HCV, the Department of Veterans Affairs now includes the FibroScan mini+ portable technology in its contract
Echosens recently recruited Dominique Legros to lead the company as global CEO. Medgadget caught up with him to learn more about the company and his goals for its future.